FDA fast-tracks psychedelic drug research following Trump executive order

The U.S. FDA has announced new measures to fast-track the development of psychedelic treatments for serious mental illnesses. This follows an executive order by President Trump, instructing federal health agencies to enhance access to emerging therapies.

Key conditions targeted include treatment-resistant depression and PTSD. "Under President Trump's leadership, we are accelerating the research, approval and responsible access to promising mental health treatments," said Robert F. Kennedy Jr. The FDA will issue priority vouchers for companies researching psilocybin for depression and methylone for PTSD.

An early-stage trial for noribogaine, aimed at alcohol use disorder, has also been cleared. The FDA emphasizes that ongoing studies will be closely monitored for safety and effectiveness.